Cassava Sciences said a study of its Alzheimer's treatment simufilam didn't meet co-primary, secondary and exploratory biomarker endpoints. Trading was halted at 7:25 a.m. ET and resumed trading at 8 ...

There's also the trailing stop-loss order, Roberts said, which adjusts based on upward movements in a stock's price ... not solely reliant on timing the market, which, as we all know, is nearly ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Trends in CEO compensation generally mirror those of the stock market, in part because pay packages for chief executives have largely been tethered to stock performance for five decades.

Finally, the study found that applying GPT-4's financial acumen to trading strategies produced more profitable trading, with higher share ratios and alpha that ultimately beat the stock market.

However, Bristol Myers’ BMY stock was up 10.5% following ABBV’s news. The studies were designed to show a statistically significant reduction (improvement) in the change from baseline in the ...

Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...

Shares in biotech firm Moderna (NASDAQ: MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

The findings from the study were presented at the AACR ... Accordingly, we expect the market sentiment surrounding the EXAS stock to remain positive surrounding this development.

Spero Therapeutics (NASDAQ:SPRO) stock tumbled 20% post-market after the company announced it was cutting its workforce by 39% in the wake of a failed Phase 2 study for its drug SPR720.

The study showed that while LD IL-2 showed significant expansion of regulatory T cell populations in the LD IL-2 q4wks group, it did not exhibit benefits in exploratory endpoints in the q2wks group.